SCHEMBL13620362

SCHEMBL13620362

COC(=O)C(Br)CCC(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZDHHC7 Q9NXF8 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.38
CA1 P00915 3/20 0.36
CA2 P00918 1/20 0.36
CA14 Q9ULX7 3/20 0.35
CA12 O43570 2/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
MME P08473 1/20 0.33
FOLH1 Q04609 1/20 0.32
PKM P14618 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
KMT2A Q03164 1/20 0.32
PTPN1 P18031 1/20 0.32
SLC1A3 P43003 1/20 0.31
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31
CAPN1 P07384 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1415237 0.91 ZDHHC7 (0.65) ZDHHC7SMN1; SMN2CA1CA2CA14
SCHEMBL5965786 0.91 ZDHHC7 (0.65) ZDHHC7SMN1; SMN2CA1CA2CA14
SCHEMBL8038666 0.85 ZDHHC7 (0.72) ZDHHC7SMN1; SMN2CA1CA2KMT2A
SCHEMBL13248927 0.81 ZDHHC7 (0.73) ZDHHC7SMN1; SMN2CA1CA2CA14
SCHEMBL1415798 0.81 ZDHHC7 (0.80) ZDHHC7SMN1; SMN2CA1CA2CA14
SCHEMBL13069761 0.81 ZDHHC7 (0.73) ZDHHC7SMN1; SMN2CA1CA2CA14
SCHEMBL719382 0.81 ZDHHC7 (0.73) ZDHHC7SMN1; SMN2CA1CA2CA14
SCHEMBL10569161 0.80 ZDHHC7 (0.41) ZDHHC7SMN1; SMN2CA1ALDH1A1GAA
SCHEMBL23795547 0.79
SCHEMBL283158 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023016518-A1 HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 四川海思科制药有限公司 2023-02-16 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF ZDHHC7 1873/4885SMN1; SMN2 3563/4885CA1 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.